▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2024 by analyst upside · 2026-11-13
SRPT
Sarepta Therapeutics, Inc.
Healthcare · Market Cap $2B · P/E 800.5x
ANALYST PRICE TARGET
+36.0%
implied upside to consensus target
Current Price $16.01
Consensus Target $21.77
Bull Target $38.0
Bear Target $5.0
Analysts Covering 22
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
6
Hold
12
Sell
4
52-Week Low $14.68
52-Week High $24.68
YTD Return -24.9%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) 800.5x
Forward P/E 10.8x
EPS (TTM) $0.02
PEG Ratio -0.09
Dividend Yield N/A
Revenue (TTM) $2.0B
Profit Margin -5.9%
52-WEEK RANGE
52-Week Low $14.68
52-Week High $24.68
Current Price $16.01
Bear Target $5.0
Bull Target $38.0
● Now $16.01 ● Target $21.77
TRADING DATA
Avg Volume 2.7M
YTD Return -24.9%
Analyst Count 22
Consensus Hold
Upside to Target +36.0%
Last Updated 2026-11-13

ANALYST SUMMARY

Sarepta Therapeutics, Inc. (SRPT) is currently trading at $16.01 with a Wall Street consensus price target of $21.77, implying potential upside of 36.0% over the next 12 months. 22 analysts currently cover SRPT, with a consensus rating of Hold - 27% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $38.0, while the most cautious has a target of $5.0.

SRPT operates in the Healthcare sector with a market capitalisation of $2B. The stock is down 24.9% year-to-date and is currently trading near the lower end of its 52-week range of $14.68 – $24.68.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for SRPT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-11-06 Building track record
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-10-08 Building track record
HC Wainwright & Co. reit
Sell → Sell 2026-10-05 31% win rate (48 calls)
JP Morgan - Reiterated
Neutral → Neutral 2026-09-30 43% win rate (7 calls)
Needham reit
Underperform → Underperform 2026-09-28 20% win rate (5 calls)
Piper Sandler - Reiterated
Neutral → Neutral 2026-07-09 14% win rate (7 calls)
Wolfe Research ↑ Upgrade
Peer Perform → Outperform 2026-07-09 Building track record
HC Wainwright & Co. reit
Sell → Sell 2026-04-16 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
26
out of 100
Coverage depth
24/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →